Introduction {#Sec1}
============

The sentinel lymph node (SLN) biopsy procedure was developed to identify and analyze the first drainage nodes of solid tumors, whose status is representative of the nodes located further along the drainage pathway. A negative SLN biopsy indicates that complete lymphadenectomy is unnecessary, thus allowing a substantial decrease in surgical morbidity. In addition, the SLN technique, and particularly preoperative lymphoscintigraphy, may help to detect aberrant drainage pathways and allows nodal ultrastaging, which is difficult to perform on a large number of nodes.

Among gynecological cancers, early cervical cancer seems a good candidate for the SLN technique. Nodal involvement is a major prognostic factor in early cervical cancer \[[@CR1]\], but is present in less than 20 % of patients at this stage \[[@CR2]\]. Nodal recurrences have been reported outside the usually sampled territories \[[@CR3]\], and most of the involved nodes correspond to low-volume disease \[[@CR4]\]. Extensive studies of SLN biopsy in this indication \[[@CR5]--[@CR7]\] have established feasibility and shown excellent detection rates and diagnostic value \[[@CR8]\].

The SLN technique initially relied on the injection of patent blue dye. Subsequently, radiocolloid injection followed by preoperative lymphoscintigraphy and intraoperative gamma-probe detection was found to increase the SLN detection rate and the sensitivity of the technique \[[@CR9], [@CR10]\]. The impact of the intraoperative detection method (patent blue, radiocolloid, or both) on the detection and diagnostic value of SLN biopsy has been extensively studied. In contrast, few data are available on SLN detection by preoperative lymphoscintigraphy. We recently reported \[[@CR8]\] that lymphoscintigraphy reduced the risk of false-negative SLN detection in patients with early cervical cancer.

The purpose of this study was to evaluate the feasibility, SLN detection rate, factors influencing the detection, and SLNs anatomic location of lymphoscintigraphy in patients with early cervical cancer. To achieve these objectives, we analyzed data from the large prospective multicenter SENTICOL study \[[@CR8], [@CR11]\].

Materials and methods {#Sec2}
=====================

Materials {#Sec3}
---------

This work is an ancillary analysis of data from the prospective multicenter SENTICOL study performed between January 2005 and June 2007 in seven French tertiary centers with expertise in laparoscopic SLN biopsy to assess the usefulness of this procedure in patients with early cervical cancer. Inclusion criteria of the SENTICOL study were squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the cervix FIGO stage IA1 with emboli to IB1; the diagnosis was confirmed by biopsy or conization, clinical examination, and pelvic MRI. Non-inclusion criteria were downstaging after chemotherapy or radiotherapy, documented allergy to patent blue or rhenium sulfide, medical history of severe allergy, age less than 18 years, pregnancy, and preoperative imaging findings suggesting lymph node involvement. Written informed consent was obtained from each patient before study inclusion, and the study was approved by the appropriate ethics committee (Comité de Protection des Personnes HEGP-Broussais, Paris). This study included 139 patients in the modified intention-to-diagnose population \[[@CR8]\]. Table [1](#Tab1){ref-type="table"} reports the main characteristics of the patients and tumors. The results of intraoperative SLN detection have been reported \[[@CR8], [@CR11]\].Table 1Characteristics of the study patients and tumorsCharacteristics*n* = 139 (%)Mean age (±SD), years44.4 (±13.6)Mean BMI (±SD), kg/m^2^23.7 (±5.5)Past history of cone biopsy, *n* (%)62 (44.6)Histology, *n* (%) Squamous cell carcinoma103 (74.1) Adenocarcinoma34 (24.4) Adenosquamous carcinoma, *n*2 (1.4)FIGO stage, *n* (%) IA1 with emboli5 (3.6) IA212 (8.6) IB1121 (87.1) IIA1 (0.7)*BMI* body mass index, *FIGO* federation of gynecology and obstetrics

Methods {#Sec4}
-------

A 4 mL-radiocolloid (99mTc-labeled colloidal rhenium sulfide, Nanocis^®^, Cis Bio International, Gif-sur-Yvette, France) injection into the four cardinal points of the cervix was performed using a 25-gauge needle on the day before (120 MBq, long protocol) or morning of (60 MBq, short protocol) surgery. A lymphoscintigraphy was performed the day before or the day of surgery depending on the centres, and early and delayed scintigraphic planar images with anterior and lateral views were obtained. The results were communicated to the surgeons before the procedure (Fig. [1](#Fig1){ref-type="fig"}a, b).Fig. 1Preoperative sentinel lymph node (SLN) detection in a patient with early cervical cancer. **a** Planar image 30 min after injection of Nanocis^®^ (4 × 400 μCi): identification of two SLNs on the *left side*, one in the inguinal territory and the other in the iliac territory. **b** Planar image 90 min after injection of Nanocis^®^ (4 × 400 μCi): identification of three SLNs in the *left* iliac territory and four SLNs in the *right* iliac territory

At the beginning of the surgical procedure, 2 mL of diluted patent blue (2.5 % in 2 mL of saline) was injected into the four cardinal points of the cervix. Intraoperative detection was performed before and after opening the peritoneum, pararectal, and paravesical spaces. The SLNs were detected based on the blue color of the lymphatic channels and nodes and on radioactivity detected using a handheld gamma probe. SLNs were electively sampled. The level of radioactivity in each SLN was measured in vivo and ex vivo, and the absence of residual in vivo radioactivity was checked. Pelvic lymphadenectomy was then performed routinely. Depending on the center, frozen-section histology was performed either routinely or only on nodes with gross changes suggesting metastasis. In the absence of node metastasis, colpohysterectomy was performed. Patients with nodal involvement underwent pelvic and para-aortic lymphadenectomy, but not hysterectomy, as chemoradiotherapy was indicated.

The numbers of SLNs detected pre-and intraoperatively were recorded, as well as their anatomic location according to Marnitz et al. \[[@CR12]\]. Typical drainage was defined as through the external iliac and interiliac basins. All other drainage basins were considered atypical. Histological examination of all SLNs was performed after hematoxylin-eosin-saffron (HES) staining of 200-μ sections. SLNs negative by HES were examined by immunohistochemistry with anti-cytokeratin AE1-AE3 (Dako, France). Non-SLNs were examined routinely after HES staining at the local center, by the pathologist who examined the SLNs. All pathologists who participated in the study were trained in SLN biopsy for breast, cervical, and endometrial cancers. Isolated tumor cells were defined as \<0.2 mm, micrometastases as between 0.2 and 2 mm, and macrometastases as \>2 mm \[[@CR13]\].

For the analysis of lymphoscintigraphic detection, all lymphoscintigrams were subjected to a centralized review by two experienced nuclear physicians and three surgeons (MF, IO, FL, PM, ASB). All radioactive LNs were considered as SLNs. Based on the results, we determined the lymphoscintigraphic detection rate and the factors affecting it, the bilateral detection rate, and the anatomic location of SLNs detected by lymphoscintigraphy.

Statistical analysis {#Sec5}
--------------------

As previously described \[[@CR8]\], the sample size (*n* = 120 patients) was calculated assuming a 20 % prevalence of lymph node involvement (1), a 90 % detection rate, a sensitivity per patient of 87.5 %, a sensitivity of 63--97 %, and a negative predictive value of 90--99 % \[[@CR14]\]. The study was carried out using the modified intention-to-diagnose approach. We first determined the detection rate. The feasibility of preoperative lymphoscintigraphy was assessed by collecting failures and complications. Pain during the injections was evaluated by the patients on a visual analog scale (VAS). The times from injection to lymphoscintigraphy and from lymphoscintigraphy to surgery were recorded.

We investigated the potential impact on lymphoscintigraphic detection of age, history of conization, body mass index (BMI), histological type, presence of emboli, and protocol (long or short). For the univariate analysis, we used logistic regression models to identify predictors of any SLN detection and of bilateral SLN detection. *P* values lower than 0.05 were considered significant. Variables from univariate analysis yielding *P* values lower than 0.20 were included in a multivariate logistic model associated with the dependent variable \[[@CR15]\], in which *P* values lower than 0.05 were considered significant. All analyses were performed using SAS software (release 9.2; SAS Institute, Cary, NC, USA).

Results {#Sec6}
=======

Sentinel lymph node (SLN) technique and feasibility of lymphoscintigraphy {#Sec7}
-------------------------------------------------------------------------

The radiocolloid injection was performed in 133 patients, of whom 131 (98.5 %) underwent preoperative lymphoscintigraphy; in the remaining 2 patients, technical problems precluded lymphoscintigraphy. The short protocol was used in 31 (23.7 %) patients and the long protocol in 98 (74.8 %) patients; the protocol was not recorded for 2 patients. Table [2](#Tab2){ref-type="table"} shows the times from radiocolloid injection to lymphoscintigraphy and from lymphoscintigraphy to surgery. Among the 98 patients who had the radiocolloid injection on the day before surgery (long protocol), 42 underwent lymphoscintigraphy on the day before surgery and 47 on the day of surgery; this information was missing for 9 patients.Table 2Preoperative detection of sentinel lymph nodes using the short and long protocolsTotalShort protocol *n* = 31Long protocol *n* = 98*P* valueLymphoscintigraphic detection rate, *n* (%)100/114 (87.8)20/27 (74.1)79/86 (91.9)0.020Bilateral lymphoscintigraphic detection rate, *n* (%)67/114 (58.8)14/27 (51.9)52/86 (60.5)NSMedian number of SLNs per patient, (Q1--Q3)2 (1--4)2 (0--3)2 (1--4)NSMedian number of right-sided SLNs per patient (Q1--Q3)1 (0--2)1 (0--1)1 (0--2)NSMedian number of left-sided SLNs per patient (Q1--Q3)1 (0--2)1 (0--1)1 (1--2)NSMedian time from radiotracer injection to lymphoscintigraphy, minutes (Q1--Q3)146 (35--900)61 (45--82)840 (30--900)\<0.001Median time from lymphoscintigraphy to surgery, min (Q1--Q3)180 (112--1156)99 (64--242)293 (135--1246)\<0.001Q1--Q3 interquartile range from the 25th to the 75th percentile*SLN* sentinel lymph node, *NS* nonsignificant

Only 1 (0.8 %) patient experienced a serious complication. The radiocolloid started to be injected, whereas she was at the beginning of a pregnancy. The injection was then stopped, but the pregnancy was terminated a few weeks later. No specific complications of lymphoscintigraphy were recorded. Pain during the injection was assessed in 46 of 131 patients: the VAS score was \<3 in 29 (63 %) patients \[9 (75 %) receiving the short and 20 (58.8 %) the long protocol\], 3--7 in 16 (34.8 %) patients \[2 (16.7 %) receiving the short and 14 (41.2 %) the long protocol\], and \>7 in 1 (2.2 %) patient (short protocol). Of the 131 lymphoscintigraphies, 114 underwent centralized review.

All 139 patients in the modified intention-to-diagnose analysis received patent blue injection followed by SLN detection and biopsy then by pelvic and/or para-aortic lymphadenectomy.

Preoperative lymphoscintigraphic detection of sentinel lymph nodes (SLNs) {#Sec8}
-------------------------------------------------------------------------

### Preoperative lymphoscintigraphic SLN detection rate {#Sec9}

The centralized review of 114 lymphoscintigrams identified 352 SLNs in 100/114 (87.8 %) patients. Median number of SLNs detected per patient was 2 (1--4) overall, 1 (0--2) for SLNs on the right side, and 1 (0--2) for SLNs on the left side. SLNs were detected bilaterally in 67/100 (67 %) patients. Table [2](#Tab2){ref-type="table"} reports the data separately for the short and long protocols.

### Factors influencing preoperative lymphoscintigraphic SLN detection {#Sec10}

By univariate analysis, factor significantly associated with a higher lymphoscintigraphic SLN detection rate was long protocol (OR 3.95, 95 % CI 1.22--12.85, *P* = 0.022). Older age was associated with a lower detection rate (OR 0.51, 95 % CI 0.33--0.75, *P* \< 0.001).

For the multivariate analysis, we used the two factors above, BMI (*P* = 0.056), and time from radiocolloid injection to lymphoscintigraphy (*P* = 0.134). Factors independently associated with SLN detection in the multivariate model were older age (OR 0.91, 95 % CI 0.87--0.96; *P* \< 0.001) and long protocol (OR 8.23, 95 % CI 1.87--36.25, *P* = 0.005). Higher BMI showed a trend toward a lower detection rate (OR 0.91, 95 % CI 0.82--1.01, *P* = 0.072).

### Factors influencing bilateral preoperative lymphoscintigraphic SLN detection {#Sec11}

By univariate analysis, factors significantly influencing bilateral SLN detection were age (OR 0.95, 95 % CI 0.93--0.98, *P* = 0.003) and time from radiocolloid injection to lymphoscintigraphy (OR 4.29, 95 % CI 1.95--9.90, *P* \< 0.001). Bilateral detection decreased with older age and increased with longer time from radiocolloid injection to lymphoscintigraphy.

The multivariate model was built using the two factors above (*P* values \<0.20), BMI (*P* = 0.079), histological type (*P* = 0.104), and histological differentiation (*P* = 0.163). In this model, factors independently associated with bilateral SLN detection were age (OR 0.95, 95 % CI 0.92--0.98, *P* \< 0.001) and time from radiocolloid injection to lymphoscintigraphy (OR 5.42, 95 % CI 2.21--13.27, *P* \< 0.001).

### Location of SLNs detected by preoperative lymphoscintigraphy {#Sec12}

Most of the SLNs detected by lymphoscintigraphy were located in the external iliac territory (60.5 %), as expected. However, substantial percentages of SLNs were in the common iliac (19.6 %) and para-aortic (10.8 %) basins. The percentage of parametrial SLNs was 6 % (Table [3](#Tab3){ref-type="table"}).Table 3Location of sentinel lymph nodes detected preoperatively by centralized review of lymphoscintigraphies and intraoperatively based on blue color and/or radioactivityLocationPreoperative SLNs, *n* (%) (*n* = 352)Intraoperative SLNs, *n* (%) (*n* = 419)External iliac + inter-iliac + internal iliac213 (60.41 %)334 (80.29 %)Common iliac69 (19.6 %)34 (8.11 %)Inguinal00Para-aortic38 (10.79 %)15 (3.58 %)Parametrium21 (6 %)30 (7.16 %)Promontory10 (2.8 %)5 (1.19 %)Mid-abdomen00Other (presacral)1 (0.3 %)0*SLN* sentinel lymph node

Intraoperative detection of sentinel lymph nodes (SLNs) {#Sec13}
-------------------------------------------------------

Intraoperative detection was performed in 136 of the 139 patients. The intraoperative detection rate using combined patent blue and radiocolloid detection was 97.8 % (89.9 % blue and 93.9 % radioactive SLNs). In all, 419 SLNs were identified (61 blue, 109 radioactive, and 249 both). Median number of SLNs detected intraoperatively per patient was 3 (2--4) overall and 1 on each side (1, 2). SLNs were detected bilaterally in 104 (76.5 %) patients. Most of the SLNs detected intraoperatively were located in the external iliac basin (79.7 %) but 8.1 % were in the common iliac basin, 3.6 % in the para-aortic basin, and 7.1 % in the parametrium.

Histological results {#Sec14}
--------------------

Of 136 patients with detected SLNs, 23 had positive SLNs and 2 had negative SLNs with positive non-SLNs. In both patients with false-negative results, the metastatic lymph nodes were located in the interiliac basin and were evenly distributed between the left and right sides. In one of these patients, a single SLN was detected by lymphoscintigraphy and during surgery, on the right side, and the metastatic non-SLN was on the left side. In the other patient, lymphoscintigraphy showed six bilateral SLNs, whereas a single SLN was detected intraoperatively, based on blue color; none of the nodes were radioactive. The time from radiocolloid injection to surgery in this patient was 16 h (960 min), which was less than the median.

Of 23 patients, 4 had metastatic SLNs in unexpected basins and 3 (3/23, 13.0 %) had node metastases located only in unexpected basins and identified only by SLN biopsy.

Discussion {#Sec15}
==========

This large prospective, multicenter study assessed lymphoscintigraphy for the preoperative detection of SLNs in patients with early cervical cancer. Lymphoscintigraphy proved both feasible and safe. When the lymphoscintigrams were subjected to centralized review, the SLN detection rate was 87.8 %, which was slightly lower than the intraoperative detection rate. Importantly, younger age and radiotracer injection on the day before surgery (long protocol) were associated with higher SLN detection rates by lymphoscintigraphy. Another finding of major clinical significance is that, although most SLNs were located in the expected drainage basins (external iliac and interiliac), a substantial proportion were in unusual basins (common iliac, 19.6 %; para-aortic, 11.8 %; and parametrium, 6 %).

The intensity of pain due to intracervical radiocolloid injection was usually acceptable, with only 1 patient reporting a VAS score greater than 7. The long protocol seemed associated with greater pain intensity than the short protocol. However, the volume injected was identical in the two protocols, and the difference in the radioactivity dose cannot explain the pain. Premedication of the patients on the day of surgery may explain the lower pain intensity with the short protocol. In addition, pain was assessed in only 46/131 patients, which may have induced bias.

Our lymphoscintigraphic detection rate (87.8 %) was within the previously reported range of 81.1--96 % \[[@CR16]--[@CR19]\]. Variability in detection rates may be ascribable to differences in injected doses and timing of the injection and lymphoscintigraphy. Importantly, we identified two factors associated with a higher detection rate, namely, younger age and long protocol (120 MBq on the day before surgery instead of 60 MBq on the morning of surgery). The known decline in lymphatic system function with advancing age may explain that younger patients more often had detectable SLNs. The long protocol involved a substantially longer time interval between the radiocolloid injection and imaging, which may have allowed the radiocolloid to travel over longer distances, thus helping to detect second- or third-tier nodes \[[@CR16]\], and increasing the detection rate.

We are aware of a single previous study, in only 32 patients, involving identification of factors associated with the SLN detection rate in patients with early-stage cervical cancer \[[@CR19]\]. Other studies assessed only the contribution of lymphoscintigraphy to intraoperative SLN detection. Our results indicate a particularly important role for lymphoscintigraphy in younger patients and support the use of the long protocol.

The detection rate was lower by lymphoscintigraphy than by intraoperative examination, in keeping with earlier data. Intraoperatively, in addition to the radiocolloid, patent blue contributes to identify SLNs. In addition, studies indicate that surgeons use the lymphoscintigraphy findings to guide their exploration, thus increasing the likelihood of identifying SLNs \[[@CR9], [@CR20]\].

The SLNs detected by lymphoscintigraphy were usually located in the external iliac territory, as expected. However, 10.8 % were in the para-aortic basin, which can be challenging to explore intraoperatively. The identification of aberrantly located drainage pathways or SLNs is a major advantage of lymphoscintigraphy. In particular, lymphoscintigraphy may show SLNs in the supra-mesenteric region, which is not usually well explored, due to the interposition of the gastrointestinal tract. The large amount of radiocolloid near the cervix limits the usefulness of lymphoscintigraphy for detecting parametrial SLNs. Nevertheless, 6 % of SLNs seen by lymphoscintigraphy in our study were in the parametrial territory, and the proportion of SLNs at this location was similar by lymphoscintigraphy and by intraoperative detection. Thus, when interpreted by experts, lymphoscintigraphy is of interest for evaluating the parametrial nodes. In our study, the external iliac, inter-iliac, and common iliac node groups could not be reliably separated and were therefore classified as external iliac. Conventional lymphoscintigraphy produces 2-dimensional images with only anterior and lateral views, which is not sufficient to separate the external iliac, interiliac, internal iliac, presacral, and common iliac nodes. Imaging by combined single-photon-emission computed tomography (SPECT) and computed tomography (CT) has been found accurate in detecting aberrant drainage pathways, including the common iliac pathway (20). Detection rates were not significantly different between lymphoscintigraphy and SPECT-CT in this study, but this last method was more accurate in determining the anatomic location of the SLNs compared to planar lymphoscintigraphy. Several other studies obtained similar results \[[@CR21]--[@CR24]\]. Nevertheless, the detection rates by planar lymphoscintigraphy were lower in these studies than in ours. In addition, SLNs were more often detected in the common iliac territory by lymphoscintigraphy than by intraoperative detection, a fact that may be ascribable to the review of the images by nuclear medicine physicians.

Our study has several limitations. The intraoperative detection protocol was standardized but the preoperative lymphoscintigraphy protocol was not. The radiocolloid was injected either on the day before surgery (long protocol) or on the morning of surgery (short protocol). Variations also occurred in the time from radiocolloid injection to imaging. The image acquisition modalities were not standardized. Furthermore all radioactive preoperative LNs were considered as SLNs, regardless of location, time of appearance, and node basin group, leading to overestimate the number of SLNs in some cases. In addition that intraoperative detection was performed with knowledge of the lymphoscintigraphy findings may have biased the comparison of pre-and intraoperative detection rates, thereby contributing to explain the higher intraoperative detection rate. However, in clinical practice lymphoscintigraphy is intended to facilitate intraoperative SLN detection, and blinding the surgeons to the lymphoscintigraphy findings would not have been ethically acceptable.

Conclusion {#Sec16}
==========

Our study demonstrates the feasibility of preoperative lymphoscintigraphy for SLN detection in patients with early cervical cancer. The lymphoscintigraphy detection rate, although lower than the intraoperative detection rate, was sufficiently high to suggest a role for preoperative lymphoscintigraphy, particularly using the long protocol. Moreover, the substantial proportion of SLNs identified by lymphoscintigraphy in unexpected territories is of major clinical significance. Surgeons can adjust their exploration procedure according to the lymphoscintigraphy results, thus increasing the likelihood of identifying SLNs. Further studies are needed to better evaluate preoperative lymphoscintigraphy detection of SLNs in patients with early cervical cancer. More specifically, the optimal lymphoscintigraphy protocol that maximizes the pre- and intraoperative detection rates must be defined.
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